Quick answer
There is an FDA-approved oral semaglutide tablet. There are also compounded oral and sublingual preparations, which are a different category with a different regulatory status. Public conversation runs the two together constantly, and almost every confusing claim about "GLP-1 pills" comes from that one collapsed distinction.
Majesta dispenses weekly injections only. We do not offer tablets, drops or sublingual preparations, and this page is an explainer rather than an offer.
Three different things called "oral GLP-1"
An approved oral tablet. Semaglutide exists in an FDA-approved tablet, reviewed and approved as a finished product by the agency. Its labeling is public: you can read it in DailyMed, the National Library of Medicine's repository of approved product labeling. Approved means the specific formulation, dose and manufacturer went through review. It does not mean the product is right for any particular person, which is a separate clinical question.
A compounded oral or sublingual preparation. Compounding is a pharmacy preparing a medication for an individual patient against a prescription. A compounded preparation is not FDA-approved as a finished product, is not a generic of any brand, and is not interchangeable with one. That is true of a compounded injection as much as a compounded tablet or drop. The route the medication takes does not change its regulatory status.
Something sold without a prescription. Anything offering semaglutide or tirzepatide with no clinician involved is not either of the above. Two questions settle it quickly: who wrote the prescription, and which licensed pharmacy filled it.
The practical consequence is that "is it a pill or a shot" tells you almost nothing about whether a product is legitimate, while "who prescribed it and who compounded it" tells you nearly everything.
What "not FDA-approved" does and does not mean
It does not mean illegal. Compounding is a long-established, lawful part of pharmacy practice, governed at the state level for the patient-specific 503A pharmacies that fill most telehealth prescriptions, and by the standards United States Pharmacopeia publishes for how compounding is actually carried out.
It does mean the finished preparation has not been through FDA premarket review for safety, effectiveness or quality. There is no approved labeling for it. So when somebody quotes a precise figure for a compounded oral or sublingual preparation, the reasonable next question is where that figure came from, because it did not come from an approved label.
What happened to the tablet and drop products in 2026
This is a matter of public record rather than interpretation, and it is easy to check.
Several telehealth companies offered compounded oral or sublingual GLP-1 preparations during 2026. Those product pages now return errors. Henry Meds pages for tirzepatide tablets, semaglutide tablets, oral semaglutide and sublingual semaglutide drops are gone. A compounded oral semaglutide product announced by Hims & Hers was reported on widely and the announcement page no longer resolves either.
The regulatory friction around compounded oral semaglutide specifically was covered at the time by Futurism, Clinical Advisor and The Cardiology Advisor, among others.
We are not going to characterise any company's internal reasoning, because we do not have it. What the record supports is narrower and still useful: these were offered, and now they are not. If you are reading an article or a forum post from earlier in the year that recommends one of them, the recommendation has outlived the product.
Why this category kept attracting claims
Injections put people off. That is a real preference and not an irrational one, so a form that removes the needle is genuinely attractive, and attractive categories attract claims. The pattern to watch for is a specific number attached to a preparation that has no approved labeling: a percentage absorbed, an equivalence to some injected dose, a potency comparison.
We are not neutral about this and it costs us something to say so. An earlier explainer we published on this same topic was withdrawn by our own compliance review, because it carried bioavailability figures we could not stand behind. Its URL still returns nothing. That is the standard this page is written to, and it is why there are no such numbers here either.
What to ask about any non-injection form
- Which pharmacy compounds it, and is that pharmacy licensed in your state. You can check with the state board of pharmacy directly.
- Is it compounded for you against a prescription, or shipped from stock. Patient-specific compounding is what a 503A pharmacy does.
- What is the beyond-use date, and how is it stored. Compounded preparations carry a pharmacy-assigned beyond-use date rather than a manufacturer expiration date.
- Who decides whether treatment is appropriate. A licensed clinician reviewing your history is a different thing from a questionnaire that approves everyone.
- What happens if you want to stop. Cancellation terms are a legitimacy signal in this category, not a detail.
What Majesta does
Two plans, both weekly injections. Essential is compounded semaglutide, Performance is compounded tirzepatide. Both are prescribed only if a US-licensed physician determines treatment is appropriate, and both are dispensed by a state-licensed 503A compounding pharmacy.
We do not offer oral or sublingual preparations. If that is specifically what you are looking for, this page is not trying to talk you out of it or into anything else; it is trying to make sure you can tell which of the three categories above you are actually being sold.
If you decide the injectable route is the one you want to understand properly, the reference guides for compounded semaglutide and compounded tirzepatide cover regulation, cost, safety, and access in depth.
Compounded medications are not FDA-approved as final products and are not generic versions of, equivalent to, or interchangeable with any brand-name medication.
Frequently Asked Questions
Are there GLP-1 pills, or is it all injections?
Both exist, but they are not the same category. There is an FDA-approved oral semaglutide tablet, reviewed and approved as a finished product, and its labeling is public in the National Library of Medicine's DailyMed repository. Separately, some telehealth companies have sold compounded oral and sublingual preparations. A compounded preparation is made for an individual patient by a pharmacy and is not FDA-approved as a finished product, whatever route it takes. The word oral does not tell you which of the two you are looking at, and that is the distinction worth getting right before anything else.
Does Majesta offer tirzepatide tablets or sublingual semaglutide?
No. Majesta dispenses weekly injections only: compounded semaglutide on the Essential plan and compounded tirzepatide on the Performance plan. We do not offer tablets, drops or any sublingual preparation, and this page is not an offer of one.
Why did companies stop selling compounded GLP-1 tablets and drops?
Several product lines were discontinued during 2026 and the pages that described them now return errors, which is how anyone can verify the withdrawals independently. The commercial and regulatory pressure around compounded oral semaglutide in particular was reported at the time by Futurism, Clinical Advisor and others. What we can say with confidence is what the record shows: the products were offered, and then they were not. We do not have visibility into any individual company's internal reasoning and will not guess at it.
Is a compounded sublingual GLP-1 safer or weaker than an injection?
This page will not answer that, and the reason is worth stating rather than hiding. Comparing how much of a drug reaches the bloodstream by different routes requires study data specific to the exact preparation, and for compounded preparations that data generally does not exist in public form. An earlier version of this topic on our site was withdrawn by our own compliance review because it carried figures we could not stand behind. Anyone quoting you a precise absorption or potency comparison for a compounded oral or sublingual GLP-1 should be asked where the number comes from.
What should I ask a provider offering a non-injection GLP-1?
Four questions cover most of it. Which pharmacy compounds it, and is it licensed in your state. Is the preparation compounded for you against a prescription, or sold from stock. What is the beyond-use date and how should it be stored. And is there a licensed clinician who evaluates whether treatment is appropriate for you at all, rather than a form that approves everyone. A provider that answers all four plainly is telling you something; one that cannot is also telling you something.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Approved semaglutide product labeling · U.S. National Library of Medicine, DailyMed
- 2.USP Compounding Standards (General Chapters 795, 797 and 800) · United States Pharmacopeia
Majesta Health medical content is written against primary sources (FDA labels, peer-reviewed trials, HHS and CDC publications) and passes a documented compliance review before publication. We are rolling out named physician review with US-licensed clinicians from our partner MD Integrations (MDI): each reviewed article will show the reviewing physician's name, NPI, and review date.
- US-licensed physicians affiliated with our clinical partner MD Integrations
- Practicing in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across states planned for launch through the MD Integrations Medical Services Organization (coverage varies by state and clinician licensure; see our states page)
- Dispensing pharmacy partner: Belmar Pharma Solutions; Majesta prescriptions are dispensed through Belmar's state-licensed 503A compounding pharmacy